212 related articles for article (PubMed ID: 27691399)
1. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches.
Farasat A; Rahbarizadeh F; Hosseinzadeh G; Sajjadi S; Kamali M; Keihan AH
J Biomol Struct Dyn; 2017 Jun; 35(8):1710-1728. PubMed ID: 27691399
[TBL] [Abstract][Full Text] [Related]
2. Role of N-glycosylation in EGFR ectodomain ligand binding.
Azimzadeh Irani M; Kannan S; Verma C
Proteins; 2017 Aug; 85(8):1529-1549. PubMed ID: 28486782
[TBL] [Abstract][Full Text] [Related]
3. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
[TBL] [Abstract][Full Text] [Related]
4. An integrated computational pipeline for designing high-affinity nanobodies with expanded genetic codes.
Padhi AK; Kumar A; Haruna KI; Sato H; Tamura H; Nagatoishi S; Tsumoto K; Yamaguchi A; Iraha F; Takahashi M; Sakamoto K; Zhang KYJ
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34415295
[TBL] [Abstract][Full Text] [Related]
5. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering.
Verkhivker G
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328351
[TBL] [Abstract][Full Text] [Related]
6. Rational affinity enhancement of fragmented antibody by ligand-based affinity improvement approach.
Ebrahimi Z; Asgari S; Ahangari Cohan R; Hosseinzadeh R; Hosseinzadeh G; Arezumand R
Biochem Biophys Res Commun; 2018 Nov; 506(3):653-659. PubMed ID: 30454702
[TBL] [Abstract][Full Text] [Related]
7. Comparative experimental/theoretical studies on the EGFR dimerization under the effect of EGF/EGF analogues binding: Highlighting the importance of EGF/EGFR interactions at site III interface.
Mehrabi M; Mahdiuni H; Rasouli H; Mansouri K; Shahlaei M; Khodarahmi R
Int J Biol Macromol; 2018 Aug; 115():401-417. PubMed ID: 29665393
[TBL] [Abstract][Full Text] [Related]
8. Graded activation and free energy landscapes of a muscarinic G-protein-coupled receptor.
Miao Y; McCammon JA
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12162-12167. PubMed ID: 27791003
[TBL] [Abstract][Full Text] [Related]
9. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.
Schmitz KR; Bagchi A; Roovers RC; van Bergen en Henegouwen PM; Ferguson KM
Structure; 2013 Jul; 21(7):1214-24. PubMed ID: 23791944
[TBL] [Abstract][Full Text] [Related]
10. Relationship between helix stability and binding affinities: molecular dynamics simulations of Bfl-1/A1-binding pro-apoptotic BH3 peptide helices in explicit solvent.
Modi V; Lama D; Sankararamakrishnan R
J Biomol Struct Dyn; 2013; 31(1):65-77. PubMed ID: 22803956
[TBL] [Abstract][Full Text] [Related]
11. Unravelling the Molecular Basis of High Affinity Nanobodies against HIV p24: In Vitro Functional, Structural, and in Silico Insights.
Gray ER; Brookes JC; Caillat C; Turbé V; Webb BLJ; Granger LA; Miller BS; McCoy LE; El Khattabi M; Verrips CT; Weiss RA; Duffy DM; Weissenhorn W; McKendry RA
ACS Infect Dis; 2017 Jul; 3(7):479-491. PubMed ID: 28591513
[TBL] [Abstract][Full Text] [Related]
12. Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity.
Holbrook MR; Slakey LL; Gross DJ
Biochem J; 2000 Nov; 352 Pt 1(Pt 1):99-108. PubMed ID: 11062062
[TBL] [Abstract][Full Text] [Related]
13. Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Ruan Z; Katiyar S; Kannan N
Biochemistry; 2017 Jan; 56(1):22-32. PubMed ID: 27936599
[TBL] [Abstract][Full Text] [Related]
14. Nanobody affinity improvement: Directed evolution of the anti-ochratoxin A single domain antibody.
Wang X; Chen Q; Sun Z; Wang Y; Su B; Zhang C; Cao H; Liu X
Int J Biol Macromol; 2020 May; 151():312-321. PubMed ID: 32084462
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics simulations and docking enable to explore the biophysical factors controlling the yields of engineered nanobodies.
Soler MA; de Marco A; Fortuna S
Sci Rep; 2016 Oct; 6():34869. PubMed ID: 27721441
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.
Sun X; Yan X; Zhuo W; Gu J; Zuo K; Liu W; Liang L; Gan Y; He G; Wan H; Gou X; Shi H; Hu J
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986511
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
[TBL] [Abstract][Full Text] [Related]
18. Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.
Park J; McDonald JJ; Petter RC; Houk KN
J Chem Theory Comput; 2016 Apr; 12(4):2066-78. PubMed ID: 27010480
[TBL] [Abstract][Full Text] [Related]
19. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
[TBL] [Abstract][Full Text] [Related]
20. Critical effects on binding of epidermal growth factor produced by amino acid substitutions.
Mehrabi M; Khodarahmi R; Shahlaei M
J Biomol Struct Dyn; 2017 Apr; 35(5):1085-1101. PubMed ID: 27212100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
